Brain+ A/S announced that a key finding from the recently released 2nd systematic Cochrane review (Woods et al., 2023) is the confirmation that medication combined with CST results in significantly larger benefits over and above that of medication alone. More specifically, patients that take part in CST demonstrate improvements in general cognition, Quality of Life, and communication, to name just a few. Specifically, patients with Alzheimer's disease benefit the most if they take part in CST while being prescribed cholinesterase inhibitors (ACHEI medication, the most common Alzheimer's
medication today), as highlighted in five studies summarized by Orrell and colleagues (2017). This highlights the synergistic effect of CST with ACHEI medication for patients with Alzheimer's disease and represents a promising avenue for pharma partnerships on combining Brain+ CST products with Alzheimer's medications, both the classic ACHEI and the newer medicines being approved. CST positioned to become global standard of care: The 2nd Cochrane review is another major support of CST, following the recommendation in 2022, where CST was recommended for global implementation in the World Alzheimer's Report 2022 and was highlighted in the World Health Organization's major report on dementia research and care. Brain+ is uniquely positioned to benefit from this positive momentum for CST, as the pioneer of digital CST and working with the global Key Opinion Leaders. CST is
now used in 37 countries, and Brain+ has initially targeted Denmark (home market), Germany, the United Kingdom and the United States.